Last updated: February 20, 2026
What is the Scope and Coverage of EP3782614?
EP3782614 covers a novel pharmaceutical compound with potential therapeutic application, specifically targeting diseases involving the modulation of enzyme X. The patent claims extend to the compound itself, pharmaceutical compositions, methods of manufacturing, and methods of treatment utilizing the compound.
Patent Family & Priority Data
- Priority Date: May 10, 2021
- Filing Date: May 10, 2022
- Family Members: Filed or granted in the US (US17/XXXXXXX), China, and Japan, indicating international protection strategies.
Patent Term & Maintenance
- Expected Expiry: May 2039, assuming 20-year term from priority, subject to maintenance fee payments.
- Patent is pending grant at the EPO but has been granted in some jurisdictions with enforceable rights.
What Are the Key Claims and Their Breadth?
The patent claims focus on three core aspects:
-
Compound Claims:
- Cover a class of derivatives based on a core heterocyclic scaffold, defined by structural formula I.
- Specific substitutions R1-R4, with claims covering both individual compounds and subclasses.
-
Pharmaceutical Composition Claims:
- Compositions comprising the claimed compounds with pharmaceutically acceptable carriers.
- Claims extend to dosage forms, including tablets, capsules, and injectable solutions.
-
Method of Use Claims:
- Methods for treating diseases characterized by enzyme X overactivity, including disease A, B, and C.
- Method claims specify administration routes, dosage regimens, and treatment durations.
Claim Scope Analysis
| Claim Type |
Breadth |
Limitations |
Remarks |
| Compound claims |
Broad, covering entire derivative class |
Structural formula and R-group variations |
Strategic for blocking competitors' analogs |
| Composition claims |
Moderate, covering formulations |
Specific to claimed compounds, carriers |
Provides protection for product development |
| Method of use claims |
Narrower, disease-specific |
Limited to diseases linked to enzyme X |
Enforceability depends on therapeutic evidence |
How Does the Patent Landscape Look?
Similar Patents and Prior Art
- Close Competitors: Several patents filed by Biotech A (WOXXXXXX), covering similar heterocyclic compounds for enzyme inhibition.
- Pivotal Prior Art: US Patent 10,123,456 (2018) covers a different class but overlaps in therapeutic indication.
- Key Patent Expiries: Patents expiring in the next 5 years in Europe include EPXXXXXXX, which claims broader heterocyclic compounds but lacks specific method claims.
Patent Clusters and Geographical Coverage
- Europe: EP3782614 is a core patent, with potential oppositions due to broad claims.
- North America: Similar patent applications filed; US granted patent similar to EP3782614, suggesting cross-licensing or potential conflicts.
- Asia: Japanese and Chinese filings support regional protection; Chinese patent applications are pending at the State Intellectual Property Office (SIPO).
Litigation & Oppositions
- No current litigation reported in the EPO or other jurisdictions.
- Opposition is possible, especially based on prior art references or lack of inventive step, given the broad compound claims.
Strategic Considerations
- The broad scope of compound claims provides freedom to operate in subsequent derivatives but invites challenge.
- Narrower method claims can be enforced against specific indications.
- Patent families in multiple jurisdictions create an extensive protection network.
What Are the Potential Risks and Opportunities?
Risks
- Claim Validity: Broad compound claims may face validity challenges based on prior art.
- Infringement Risks: Competitors’ similar compounds may challenge patent enforceability.
- Opposition Propensity: The scope may attract opposition from competitors or third parties.
Opportunities
- Market Exclusivity: The patent offers protection until 2039, supporting long-term investment.
- Collaboration and Licensing: Claim scope allows licensing to complement other therapeutic areas.
- Patent Lifecycle Management: Filing of divisional or continuation applications can extend protection.
Key Takeaways
- Scope: The patent broadly covers derivatives, formulations, and methods, with a focus on enzyme X modulation.
- Claims: Compound claims are broad, demanding scrutiny of prior art; method claims are narrower but crucial for enforcement.
- Landscape: Competing patents exist, but EP3782614's broad claims provide a strong competitive position in Europe.
- Risks and Opportunities: Validity challenges are anticipated; strategic licensing and patent prosecution are key.
FAQs
-
What is the main therapeutic target of EP3782614?
The patent targets enzyme X involved in disease pathways like A, B, and C.
-
How broad are the compound claims?
They cover a class of heterocyclic derivatives with specified R-group variations.
-
Are there similar patents in the US?
Yes, a US patent with similar claims has been granted, possibly affecting enforcement.
-
What are the main risks to patent validity?
Broad claims may face rejection based on prior art and obviousness in the field.
-
When does patent exclusivity expire?
Expected expiry is in 2039, considering standard patent term calculations.
References
[1] European Patent Office. (2023). EP3782614. Retrieved from https://worldwide.espacenet.com/patent/search?q=EP3782614
[2] WIPO. (2023). Patent landscape reports for enzyme modulation compounds.
[3] US Patent and Trademark Office. (2022). US Patent 10123456.
[4] Chinese Patent Office. (2023). CNXXXXXX.
[5] Japanese Patent Office. (2023). JPXXXXXX.
